Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Payables (2022 - 2026)

HeartSciences' Payables history spans 5 years, with the latest figure at $3.5 million for Q1 2026.

  • For Q1 2026, Payables rose 19.76% year-over-year to $3.5 million; the TTM value through Jan 2026 reached $3.5 million, up 19.76%, while the annual FY2025 figure was $2.9 million, 202.67% up from the prior year.
  • Payables reached $3.5 million in Q1 2026 per HSCS's latest filing, up from $817390.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $3.5 million in Q1 2026 to a low of $396506.0 in Q3 2024.
  • Average Payables over 5 years is $1.7 million, with a median of $1.5 million recorded in 2023.
  • The largest YoY upside for Payables was 360.11% in 2025 against a maximum downside of 69.08% in 2025.
  • A 5-year view of Payables shows it stood at $1.9 million in 2022, then soared by 30.13% to $2.5 million in 2023, then rose by 5.52% to $2.6 million in 2024, then plummeted by 69.08% to $817390.0 in 2025, then surged by 329.47% to $3.5 million in 2026.
  • Per Business Quant, the three most recent readings for HSCS's Payables are $3.5 million (Q1 2026), $817390.0 (Q4 2025), and $1.8 million (Q3 2025).